(Sunday, 7/14/2019)
Room: ePoster Forums
Purpose: Illustrate the method that we used at MCI to implement the new FDA approved radio pharmaceutical Lu-177 for neuroendocrine Tumors. This presentation is specifically highlighting the coordination efforts to consolidate all the aspects of Lu-177 therapy in the Radiation Oncology Department (including the injection of Amino Acids and peptide receptors as well as the Radio pharmaceutical).
Methods: Work- flow development, multiple meetings, implementation, Calibration and coordination with Nuclear Medicine, Radio-active Assay, Pharmacy. Quality Assurance and Safety along with licensing issues related to this process.
Results: Successful implementation of Lu-177 treatment at the Radiation Oncology Department of Miami Cancer Institute.
Conclusion: We were able to treat the Lu-177 patient at Radiation Oncology Department at MCI.
Keywords
Not Applicable / None Entered.
Taxonomy
IM/TH- Radiopharmaceutical therapy: Safety, QA, and radiation protection
Contact Email
